###begin article-title 0
Myeloperoxidase Promoter Polymorphism -463G Is Associated With More Severe Clinical Expression of Cystic Fibrosis Pulmonary Disease
###end article-title 0
###begin p 1
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
The severity of cystic fibrosis (CF) pulmonary disease is not directly related to CFTR genotype but depends upon several parameters, including neutrophil-dominated inflammation. Identification of agents modulating inflammation constitutes a relevant goal. Myeloperoxidase (MPO) is involved in both microbicidal and proinflammatory neutrophil activities. The aim of this study was to evaluate whether the -463GA MPO promoter polymorphism is linked to clinical severity of CF-associated pulmonary inflammation. This polymorphism significantly affects the level of MPO gene expression in leukocytes and the G allele is more expressing than the A allele. We show that MPO genotype significantly influences the severity of pulmonary disease in early stages, prior to the development of chronic lung infections, with GG genotype being associated with more severe CF disease. Our findings indicate that the level of MPO gene expression influences the CF pathogenesis, presumably reflecting cellular damage by MPO-generated oxidants or other activity of MPO in airway inflammation.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 150 151 150 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 352 353 352 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 355 356 355 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 475 476 475 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 478 479 478 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 680 681 680 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 973 995 973 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pseudomonas aeruginosa</italic>
###xml 997 1009 997 1009 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P aeruginosa</italic>
###xml 1012 1013 1012 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 1015 1016 1015 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 1213 1214 1213 1214 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1215 1216 1215 1216 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1212 1216 1212 1216 <chem-struct xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H<sub>2</sub>O<sub>2</sub></chem-struct>
###xml 1219 1220 1219 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1222 1224 1222 1224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1308 1309 1308 1309 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1310 1311 1310 1311 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1307 1311 1307 1311 <chem-struct xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H<sub>2</sub>O<sub>2</sub></chem-struct>
###xml 1347 1348 1347 1348 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1345 1348 1345 1348 <chem-struct xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cl<sup>&#8722;</sup></chem-struct>
###xml 1383 1387 1383 1387 <chem-struct xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HOCl</chem-struct>
###xml 1390 1392 1390 1392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 1395 1399 1395 1399 <chem-struct xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HOCl</chem-struct>
###xml 1640 1642 1640 1642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 1769 1771 1769 1771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1857 1859 1857 1859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 927 935 <span type="species:ncbi:9606">patients</span>
###xml 973 995 <span type="species:ncbi:287">Pseudomonas aeruginosa</span>
###xml 1586 1594 <span type="species:ncbi:9606">patients</span>
Cystic fibrosis (CF) is a lethal autosomal recessive disorder which is caused by mutation of the cystic fibrosis transmembrane regulator (CFTR) gene [1]. Although CF is a multiorgan disease, most of the morbidity and the mortality are due to progressive pulmonary disease with lung parenchymal destruction and chronic pulmonary bacterial colonization [2, 3]. There is a hypersecretion and a massive influx of neutrophils within the airways which mediate deleterious effects [4, 5]. Moreover, the intensity of the airway inflammation is directly correlated with the clinical status as evidenced by a close correlation between respiratory scores and neutrophil-derived proteinases [6]. The airway inflammation typical of CF relies thus on the paradox of misdirected neutrophil microbicidal activity resulting in an exacerbation of neutrophil-mediated tissue damage and a concomitant failure in the antimicrobial system, since CF patients can become chronically infected with Pseudomonas aeruginosa (P aeruginosa) [7, 8]. Activation of the neutrophil results in the oxidative burst which occurs at the level of NADPH oxidase leading to the generation of superoxide anion which can dismutate into hydrogen peroxide (H2O2) [9, 10]. Myeloperoxidase (MPO), an enzyme contained in azurophil granules, catalyzes the H2O2-dependent oxidation of chloride (Cl-), which yields hypochlorous acid (HOCl) [11]. HOCl is a potent microbicidal agent and a toxic chlorinating oxidant. MPO released from activated neutrophils can also damage bystander cells at inflammatory sites. Airway secretions from CF patients contained high concentrations of active MPO [12] that could catalyze protein tyrosine oxidation and produce high levels of dityrosine, 3-chlorotyrosine, and 3-nitrotyrosine [13]. Levels of MPO were correlated with poor clinical conditions and sputum production [14], thus demonstrating that extracellular MPO could contribute to hypersecretion, bronchial injury, and respiratory failure in CF. MPO could be a critical parameter in the modulation of inflammation and/or infection because MPO is involved in both microbicidal and proinflammatory activities of neutrophils.
###end p 4
###begin p 5
###xml 440 442 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 154 162 <span type="species:ncbi:9606">children</span>
###xml 507 515 <span type="species:ncbi:9606">children</span>
###xml 813 821 <span type="species:ncbi:9606">patients</span>
When we have studied purified circulating neutrophils in CF, we provided evidence of a significant increase in MPO-dependent oxidant formation in both CF children and their parents as compared to controls, whereas NADPH activity was similar to that of controls. This increased intracellular MPO activity observed in CF homozygotes and heterozygotes was observed at the basal level as well as following PMA or opsonized zymosan stimulation [15]. The fact that this increase was observed in the parents of CF children, which are heterozygous for CFTR mutation but are free of clinical symptoms, led us to the conclusion that the disturbance in MPO activity observed in CF was constitutive, independent from infection. These prior studies demonstrated that increased MPO activity could potentiate inflammation in CF patients.
###end p 5
###begin p 6
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 525 527 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 528 530 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 554 556 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 581 583 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 606 608 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 650 652 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 654 656 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 681 683 681 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 811 813 811 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 1024 1026 1024 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 1087 1089 1087 1089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 1472 1474 1468 1470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 1593 1595 1589 1591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 1860 1862 1856 1858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 559 562 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1629 1634 <span type="species:ncbi:9606">human</span>
In the present study, we asked whether a functional MPO promoter polymorphism influenced their clinical outcome. The -463G/A polymorphism is linked to the differences in MPO expression levels [16, 17]: the -463G/A promoter polymorphism significantly affects the level of MPO gene expression in bone marrow precursors and in descendant leukocytes. The G allele is more expressing than the A allele. This polymorphism is linked to incidence or severity of inflammatory diseases including atherosclerosis [18, 19], Alzheimer's [20-22], MPO-ANCA vasculitis [23], HCV-induced fibrosis [23], multiple sclerosis [24], periodontal disease [25], lung cancer [26, 27], and myeloid leukemia [24]. This polymorphism is in an Alu element, within a cluster of four hexamer half sites recognized by various nuclear receptors [17] and termed an Alu receptor response element (AluRRE). These hexamers are organized as direct repeats with spacing of two-four-two base pair. The -463A is in hexamer 1 within an estrogen receptor binding site [16], while -463G promotes binding by SP1 transcription factor [17]. The hexamer 3/4 pair is recognized by retinoic acid receptor and PPARgamma as heterodimers with retinoid X receptor (RAR-RXR), while the middle DR-4 pair (hexamers 2/3) is recognized by thyroid hormone receptor (TR-RXR). The -463GG genotype has been linked to higher MPO mRNA and protein expression than GA/AA genotypes in primary myeloid leukemia cells and monocyte-macrophages [28], while in transfection assays, the -463G promoter element supported higher expression of a reporter gene than -463A [17]. In a recent study performed in human monocyte-derived macrophages, we have provided evidence that MPO gene expression was downregulated as iNOS (inductible nitric oxide synthase) was upregulated, thus suggesting a potential connection between these two enzymes [29]. Because NO has physiological importance in airways, a difference in MPO expression levels could be relevant in the pulmonary disease in CF.
###end p 6
###begin p 7
###xml 580 581 580 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 758 760 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 799 801 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 823 825 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 916 918 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 1056 1058 1056 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
###xml 354 362 <span type="species:ncbi:9606">patients</span>
###xml 466 474 <span type="species:ncbi:9606">patients</span>
###xml 515 523 <span type="species:ncbi:9606">patients</span>
###xml 1027 1035 <span type="species:ncbi:9606">patients</span>
MPO could be considered a candidate for potential genetic modifiers of disease severity in patients with CF not necessarily related to infection. Indeed, MPO can also play a significant proinflammatory role in the absence of infection, in atherogenesis, or in neurodegenerative diseases. The mechanisms leading to neutrophil-dominated inflammation in CF patients as well as the relationships with CFTR mutations remain largely unknown. The course of lung disease in patients with CF varies considerably, even among patients with the same CFTR who are receiving standardized care [7]. This variation is largely unexplained. So far, several genes implicated in innate immunity and in the control of inflammation have been studied as potential modifiers of CF [30]. Among them, mannose-binding lectin [31], alpha-antitrypsin [32], glutathione S-transferase, TNF-alpha, IL-1 beta, and IL-1 RA have already been studied [33]. Interestingly, a possible link between the NOS1 gene locus and the rate of decline in lung function in CF patients has been described [34]. So far, there is no data available on the influence of MPO genotype on the clinical course of CF.
###end p 7
###begin p 8
###xml 224 232 <span type="species:ncbi:9606">patients</span>
###xml 338 346 <span type="species:ncbi:9606">patients</span>
In the present study, we investigate the influence of the MPO promoter polymorphism on the clinical severity of CF disease. Our results clearly demonstrate that MPO genotype influences the severity of the lung disease in CF patients in the absence of infection, with the GG genotype associated with more severe CF disease. In infected CF patients, the GG genotype was associated with an increase in the circulating neutrophil inflammatory state.
###end p 8
###begin title 9
METHODS
###end title 9
###begin title 10
Study population
###end title 10
###begin p 11
###xml 556 558 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 820 822 818 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
###xml 161 169 <span type="species:ncbi:9606">patients</span>
###xml 458 465 <span type="species:ncbi:9606">Patient</span>
###xml 504 512 <span type="species:ncbi:9606">patients</span>
Eighty eight patients with CF including 45 males and 43 females (mean age: 17.8 +/- 0.74 years) were recruited for the study. Informed consent was obtained from patients or their parents and the clinical research was conducted according to the guidelines of the French Institut National de la Sante et de la Recherche Scientifique (INSERM) and the French ethics committee. CF was diagnosed according to the standard criteria including a sweat chloride test. Patient's clinical status was evaluated in CF patients by the Shwachman-Kulczycki scoring system [35] which includes nutritional criteria, the highest value being 100. The pulmonary function was assessed by spirometry and expressed as percent-predicted FEV1 (forced expiratory volume in one second) and FVC (forced vital capacity) normalized for age and height [36]. The severity of lung disease was evaluated according to the chest radiograph and the number of radiologic lesions (obstructive lesions and segmental or diffuse bronchiectasis were counted).
###end p 11
###begin p 12
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 310 311 308 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
###xml 43 51 <span type="species:ncbi:9606">patients</span>
###xml 394 402 <span type="species:ncbi:9606">patients</span>
The lung infection was determined in 77 CF patients on the basis of bacteriological analysis of sputum, which was collected according to the methodology previously described [36]. On the basis of sputum bacterial qualitative and quantitative analysis, bronchial infection was defined as bacterial counts >/= 108 colony forming units (CFU)/l in at least 3 cultures at one-month interval, and CF patients were stratified into three groups.
###end p 12
###begin p 13
###xml 102 114 102 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P aeruginosa</italic>
###xml 40 48 <span type="species:ncbi:9606">children</span>
###xml 62 70 <span type="species:ncbi:9606">children</span>
###xml 192 200 <span type="species:ncbi:9606">children</span>
A first group designated "uninfected CF children" included 32 children without history or evidence of P aeruginosa infection. At the time of testing, sputum cultures were all negative and all children were stable and clinically well.
###end p 13
###begin p 14
###xml 96 128 96 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Staphylococcus aureus (S aureus)</italic>
###xml 130 131 130 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 167 179 167 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P aeruginosa</italic>
###xml 181 182 181 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 41 49 <span type="species:ncbi:9606">children</span>
###xml 66 74 <span type="species:ncbi:9606">children</span>
###xml 96 117 <span type="species:ncbi:1280">Staphylococcus aureus</span>
The second group designated "infected CF children" included 45 CF children either infected with Staphylococcus aureus (S aureus) (n = 8) or chronically colonized with P aeruginosa (n = 37).
###end p 14
###begin title 15
Analysis of CFTR mutations by PCR and direct sequencing
###end title 15
###begin p 16
###xml 65 67 65 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 68 70 68 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 17 25 <span type="species:ncbi:9606">patients</span>
Genotyping of CF patients was performed as previously described [37-39]. In the CF population tested, 73% carried the delta F508 mutation with 50% being delta F508 homozygote, 23% being delta F508 heterozygote with an unknown mutation, and 27% having mutations other than delta F508 at both alleles as previously described [36].
###end p 16
###begin title 17
Determination of MPO genotype by allelic discrimination assay
###end title 17
###begin p 18
###xml 499 500 499 500 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</bold>
###xml 552 553 552 553 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
DNA was isolated from leukocytes by proteinase K digestion followed by phenol extraction and ethanol precipitation. DNA (100 ng) was used in the ABI 7900 allelic discrimination assay using dual fluorophore probes which discriminate between alleles based on the single base mismatch. Primers and probes, designed using the Primer Express 2.0 software (ABI), are as follows: forward primer, 5'-AATCTTGGGCTGGTAGTGCTAAA-3'; reverse primer, 5'-GCCAGGCTGGTCTTGAACTC-3'; -463A specific probe, 5'-FAM TCCACCTGCCTCAG MGB; and -463G specific probe, 5'-VIC TCCACCCGCCTCA MGB. Probes are labeled at the 5' end with the fluorophores FAM or VIC and are stabilized by a minor groove binding moiety (MGB). Endpoint allelic specific fluorescence was measured on the ABI prism 7900 using the Sequence Detection Systems 2.0 software for allelic discrimination.
###end p 18
###begin title 19
Statistical analysis
###end title 19
###begin p 20
###xml 138 139 138 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Statistical analysis was performed using the Statview software. Comparisons were made by analysis of variance (ANOVA) or unpaired Student t test. Data are expressed as mean +/- standard error of the mean (SEM).
###end p 20
###begin title 21
RESULTS
###end title 21
###begin title 22
###xml 34 42 <span type="species:ncbi:9606">patients</span>
Frequencies of MPO genotype in CF patients as compared to control population
###end title 22
###begin p 23
###xml 62 69 62 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 40 48 <span type="species:ncbi:9606">children</span>
We determine the MPO genotype for 79 CF children. As shown in Table 1, there is no difference in the percentages of the GG, GA, or AA genotypes in the CF population as compared to the frequencies within normal European populations [16, 26, 40]. When the cases were stratified by gender, there was no statistically significant difference.
###end p 23
###begin title 24
Influence of MPO genotype on clinical parameters of CF disease
###end title 24
###begin p 25
###xml 346 354 346 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S aureus</italic>
###xml 379 391 379 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P aeruginosa</italic>
###xml 484 485 484 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 526 534 524 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S aureus</italic>
###xml 557 558 555 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 579 580 575 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 613 625 609 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P aeruginosa</italic>
###xml 648 649 644 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 671 672 665 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 746 754 740 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S aureus</italic>
###xml 771 783 765 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P aeruginosa</italic>
###xml 806 807 800 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1006 1018 1000 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P aeruginosa</italic>
###xml 1065 1072 1059 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
###xml 180 188 <span type="species:ncbi:9606">patients</span>
###xml 316 324 <span type="species:ncbi:9606">patients</span>
###xml 401 409 <span type="species:ncbi:9606">patients</span>
###xml 432 435 <span type="species:ncbi:12672?0.125">FEV</span>
###xml 547 555 <span type="species:ncbi:9606">patients</span>
###xml 638 646 <span type="species:ncbi:9606">patients</span>
###xml 726 729 <span type="species:ncbi:12672?0.125">FEV</span>
###xml 796 804 <span type="species:ncbi:9606">patients</span>
###xml 952 960 <span type="species:ncbi:9606">patients</span>
###xml 977 985 <span type="species:ncbi:9606">patients</span>
###xml 1043 1051 <span type="species:ncbi:9606">patients</span>
###xml 1099 1107 <span type="species:ncbi:9606">children</span>
###xml 1159 1167 <span type="species:ncbi:9606">children</span>
###xml 1204 1207 <span type="species:ncbi:12672?0.125">FEV</span>
###xml 1454 1462 <span type="species:ncbi:9606">patients</span>
###xml 1483 1491 <span type="species:ncbi:9606">patients</span>
###xml 1583 1591 <span type="species:ncbi:9606">patients</span>
###xml 1648 1656 <span type="species:ncbi:9606">patients</span>
###xml 1756 1764 <span type="species:ncbi:9606">patients</span>
Since clinical conditions in CF patients are greatly influenced by recurrent infections, it was relevant to evaluate the influence of MPO genotype within a homogeneous group of CF patients according to infectious/inflammatory criteria. When comparing the respiratory scores between the first group of noninfected CF patients, the second group of S aureus, and the third group of P aeruginosa-infected patients, it appeared that the FEV was significantly different in the noninfected (n = 32, 79.3 +/- 3.9) versus the group of S aureus-infected CF patients (n = 8, 56.75 +/- 5.2, P = .009) and versus the group of P aeruginosa-infected CF patients (n = 37, 60.55 +/- 4.1, P = .002). In contrast, there was no difference in the FEV in the group of S aureus- as compared to P aeruginosa-infected CF patients (P = .674). As a result, for further analysis, only two homogeneous groups, in terms of severity of CF disease, will be considered: noninfected CF patients and infected CF patients, mainly composed of P aeruginosa chronically infected CF patients. As shown in Table 2, the group of infected CF children clearly differed from the groups of noninfected CF children on the basis of respiratory scores (FEV or FVC) or infectious score measured as the number of antibiotherapies during the past year. Although not statistically significant, there was a clear difference in the Shwachman and in the radiographic scores between noninfected and infected CF patients; the noninfected CF patients having more severe Shwachman and radio scores. Of note, the mean age of the noninfected CF patients was significantly lower than the age in the infected CF patients. This could be expected since infection occurs in the course of the disease and thus affects older patients.
###end p 25
###begin p 26
###xml 127 138 127 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1(a)</xref>
###xml 289 290 285 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 417 418 409 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 989 996 969 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">Table 3</xref>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 171 179 <span type="species:ncbi:9606">patients</span>
###xml 210 213 <span type="species:ncbi:12672?0.125">FEV</span>
###xml 220 228 <span type="species:ncbi:9606">patients</span>
###xml 343 351 <span type="species:ncbi:9606">patients</span>
###xml 804 812 <span type="species:ncbi:9606">patients</span>
###xml 918 926 <span type="species:ncbi:9606">patients</span>
Within each group, either the noninfected or the infected CF patients, we evaluated the influence of MPO genotype. As shown in Figure 1(a), in the group of noninfected CF patients, there is significantly lower FEV in CF patients with GG than GA genotype (73.5 +/- 5.6 versus 95.7 +/- 8.2, P = .03). Likewise, FVC was significantly lower in CF patients with GG genotype than with GA (80.8 +/- 4.0 versus 99.7 +/- 6.7, P = .01, resp). As expected, there was more lesions seen on chest radiography in GG than in GA (23.6 +/- 8.6 versus 5.5 +/- 1.5, resp). Shwachman scores were decreased in the group of GG genotype as compared to GA (64.3 +/- 9.1 versus 87.8 +/- 3.4, resp). The number of antibiotherapies was higher in GG than in GA (3.5 +/- 1.2 versus 2.4 +/- 0.8, resp). Of note, the mean age of the CF patients was not different between the groups of GG and GA providing evidence that there was no artifact of older patients in GG group explaining their more severe clinical expression (Table 3).
###end p 26
###begin p 27
###xml 191 202 191 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1(b)</xref>
###xml 894 906 886 898 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P aeruginosa</italic>
###xml 956 964 948 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S aureus</italic>
###xml 41 49 <span type="species:ncbi:9606">patients</span>
###xml 178 181 <span type="species:ncbi:12672?0.125">FEV</span>
###xml 256 259 <span type="species:ncbi:12672?0.125">FEV</span>
###xml 266 274 <span type="species:ncbi:9606">patients</span>
###xml 859 867 <span type="species:ncbi:9606">children</span>
###xml 933 941 <span type="species:ncbi:9606">children</span>
In contrast, in the group of infected CF patients, there was no significant difference in clinical parameters between GG and GA genotypes evaluated either by respiratory scores (FEV or FVC) (Figure 1(b)) or by radiography scores. There is no difference in FEV in CF patients with GG or GA genotype (61.0 +/- 5.4 versus 59.6 +/- 4.7, resp). Likewise, no difference was observed in FVC with GG or with GA genotype (73.1 +/- 4.6 versus 74.2 +/- 4.3, resp). It could be noted, however, that the Shwachman score was higher in the group of GA than in the group of GG phenotype, but this increase was not statistically significant. With regard to the number of antibiotherapies in the preceding year, there was no significant difference. Interestingly, this lack of influence of MPO genotype on clinical parameters was observed separately both in the subgroup of CF children chronically infected with P aeruginosa and in the subgroup of CF children infected with S aureus (data are not shown).
###end p 27
###begin p 28
###xml 284 296 284 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P aeruginosa</italic>
###xml 175 183 <span type="species:ncbi:9606">patients</span>
Taking together, our data strongly suggest that the MPO genotype influences the clinical course of the disease with less severity for the GA allele versus the GG allele in CF patients, in the absence of infection. In contrast, as far as there is an infection and especially a chronic P aeruginosa infection, MPO genotype is not as discriminative, and the GA genotype is not associated with better clinical status.
###end p 28
###begin title 29
Influence of gender
###end title 29
###begin p 30
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 418 426 <span type="species:ncbi:9606">patients</span>
Since a number of studies have shown that the influence of MPO genotype could be gender-specific [20, 23], we compared the influence of MPO genotype in CF females and CF males. No influence of gender was observed. We confirmed that, in the absence of infection, in either CF females or CF males, the GG genotype was associated with a more severe lung disease and worse clinical conditions. In the group of infected CF patients, there was no significant influence of MPO genotype in CF females or males, thus corroborating the results found in the mixed population.
###end p 30
###begin title 31
Influence of the CFTR mutation
###end title 31
###begin p 32
###xml 3 11 <span type="species:ncbi:9606">patients</span>
###xml 161 169 <span type="species:ncbi:9606">patients</span>
###xml 551 559 <span type="species:ncbi:9606">patients</span>
###xml 813 820 <span type="species:ncbi:9606">patient</span>
CF patients were stratified into two groups according to their CFTR mutation, either homozygotes DeltaF508/DF508 or heterozygotes DeltaF508/others. The group of patients having the CFTR genotype corresponding to other/other was so small that we could not perform analysis. Within the group of DeltaF508/DF508 or within the group of DeltaF508/others, we confirmed what we have found for the whole population, which is that the GA phenotype was associated with better clinical parameters as compared with GG, in the absence of infection. In infected CF patients, there was no effect of MPO genotype whatever the CFTR genotype. These results concerning the influence of CFTR mutation on the clinical severity of the disease are not surprising since the CFTR genotype is not related to the inflammatory status of the patient, and it is now well documented that there is no correlation between CFTR genotype and the evolution of lung disease.
###end p 32
###begin title 33
DISCUSSION
###end title 33
###begin p 34
Our present findings establish for the first time that the GG MPO genotype is associated with more severe clinical expression of CF disease in the absence of infection. The G allele is the higher expressing allele, and the GG genotype is most often associated with worse disease. Thus, the findings in this paper linking GG genotype to worse outcome in CF is consistent with most prior studies.
###end p 34
###begin p 35
###xml 596 608 596 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P aeruginosa</italic>
###xml 612 620 612 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S aureus</italic>
###xml 1259 1261 1259 1261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 1414 1416 1414 1416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 1418 1420 1418 1420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 1759 1771 1759 1771 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P aeruginosa</italic>
###xml 1815 1817 1815 1817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 1889 1891 1889 1891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 6 14 <span type="species:ncbi:9606">patients</span>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
###xml 529 537 <span type="species:ncbi:9606">patients</span>
###xml 555 563 <span type="species:ncbi:9606">patients</span>
###xml 818 826 <span type="species:ncbi:9606">patients</span>
###xml 852 860 <span type="species:ncbi:9606">patients</span>
###xml 1315 1323 <span type="species:ncbi:9606">patients</span>
In CF patients, the association of the higher expressing GG genotype with more severe disease in the absence of infection implies that MPO enzyme contributes to the inflammatory status in noninfected patients. Our data suggest a significant proinflammatory role for MPO in the early phase of CF, in the absence of infection. Several hypotheses can be made to explain the influence of MPO in airways in the absence of infection and the potential mechanisms resulting in the presence of MPO within airways. Firstly, noninfected CF patients means that these patients are non-chronically infected by P aeruginosa or S aureus and they do not have any detectable infection demonstrated by negative bacterial analysis of the sputum at the time of the clinical analysis. In our study, we differentiated between noninfected CF patients and chronically infected patients because their clinical status were significantly different. However, our classification does not rule out some subclinical infection, which could explain the presence of some neutrophils within the lung. Secondly, it has been described that there is a "constitutive" inflammatory process in CF epithelial cells with a basal activation of the transcription factor NF-kB in the absence of infection [41]. It has been reported that epithelial cells from CF patients have the ability to secrete more IL-8, which is a potent chemoattractant for neutrophils [42, 43]. It can be hypothesized that inflammatory cytokines could attract neutrophils and/or upregulate MPO in macrophage in the absence of infection. The inhibitory role of MPO on the regulation of NOS might also explain the better clinical conditions associated with the GA genotype (producing less MPO). Indeed, epithelium-derived NO reduced P aeruginosa adherence and enfance killing of bacteria [44], and NOS expression decreased in CF as airway inflammation increases [45]. A combined study of NOS and MPO gene expression and polymorphisms might be relevant to CF and would help to understand the variability of the clinical expression of the pulmonary disease.
###end p 35
###begin p 36
###xml 186 198 186 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P aeruginosa</italic>
###xml 425 433 425 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S aureus</italic>
###xml 437 449 437 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P aeruginosa</italic>
###xml 27 35 <span type="species:ncbi:9606">patients</span>
###xml 98 106 <span type="species:ncbi:9606">patients</span>
###xml 477 485 <span type="species:ncbi:9606">patients</span>
In chronically infected CF patients, the GA genotype is not as beneficial as it is in noninfected patients. The observation that GG genotype is not associated with greater resistance to P aeruginosa or fewer infection per year suggests that MPO does not play a critical role in the antimicrobial systems of CF neutrophils. In this situation, many neutrophils are recruited within airways and these fail to kill the bacteria (S aureus or P aeruginosa). One would expect that CF patients having more MPO (GG genotype) would be more efficient in killing bacteria and thus would have less severe pulmonary disease. We do not see any difference in the severity of the pulmonary disease between GG and GA genotypes who are chronically infected.
###end p 36
###begin p 37
###xml 317 329 317 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P aeruginosa</italic>
###xml 1114 1116 1114 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 1240 1242 1240 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">47</xref>
###xml 1481 1483 1481 1483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 862 870 <span type="species:ncbi:9606">patients</span>
###xml 1104 1112 <span type="species:ncbi:9606">patients</span>
Our study thus emphasized that MPO contributes significantly to the proinflammatory effects of PMN. In the absence of infection, genotype GG may be more deleterious due to exacerbation of the inflammatory process and production of more oxidants which damage the airways and epithelium. When chronic colonization with P aeruginosa occurs, the increased production of chlorinated oxidants could be an advantage, counterbalancing the negative impact of oxidative damage to the epithelium, such that GG genotype may have both positive and negative impact; thus the difference between GG and GA is less noticeable. Moreover, additional physiopathological mechanisms are involved in the destruction of airways depending on the bacteria, thus masking the clear-cut influence of MPO genotype on the clinical expression of CF disease that we have observed in noninfected patients. Another interesting aspect of our results is the fact that MPO activity could result in the formation of inflammatory mediators by oxidizing mucus components, as it has previously been reported for plasma components in hemodialyzed patients [46]. Indeed, it has been reported that neutrophils components, especially elastase, can stimulate mucus secretion in airways [47] via an oxidant-dependent mechanisms. It would be pertinent to study whether MPO-modified mucins could have some inflammatory activities. This could fit with the data that MPO levels in neutrophils were correlated with sputum production [14], thus suggesting that MPO could be linked with CF mucus hypersecretion.
###end p 37
###begin p 38
###xml 1028 1030 1028 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B48">48</xref>
###xml 731 739 <span type="species:ncbi:9606">patients</span>
###xml 932 940 <span type="species:ncbi:9606">patients</span>
Several studies on the mechanisms of inflammation in CF have now shown that a genetic disease like CF is not as simple as originally envisioned. The cloning of the CFTR was a major milestone in understanding the molecular basis of CF, but dissecting the pathogenesis of CF has proven far more complicated. The challenge remains to select appropriate gene polymorphisms and investigate their effects in order to achieve a more complete understanding of the pathogenesis of a disease as complex as CF. The identification of a collection of modifying genotypes could lead to a more refined understanding of specific disease. In a study focused on potential genetic modifiers of disease severity in chronic granulomatous disease (CGD) patients, genotype of MPO and Fc gamma RIII were found to be strongly associated with an increased risk for gastrointestinal complications. There were, however, no data on MPO activity in PMN from CGD patients or addressing the possibility that MPO genotype could modulate levels of MPO activity [48].
###end p 38
###begin p 39
###xml 462 470 <span type="species:ncbi:9606">patients</span>
Understanding the role of modifying genes has considerable potential for determining risk profile that might impact therapeutic decisions. By subclassifying disease, according to secondary genetic risk factors, therapy could be adapted to individuals need. Indeed, the current study strongly suggest that pharmacological modulation of MPO activity could have different effects depending on MPO genotype and MPO inhibitors may have a more beneficial effect in CF patients having GG phenotype.
###end p 39
###begin p 40
###xml 515 523 <span type="species:ncbi:9606">patients</span>
In summary, our hypothesis is that, in CF, the MPO promoter polymorphism -463G/A, which influences the amount of neutrophil MPO, could modulate inflammatory and/or infection processes, thereby modulating the severity of the pulmonary disease. MPO-HOCl is known to oxidize a variety of biological molecules, and can have significant impact at inflammatory sites, independent of infection. This is likely to explain the observed difference between the MPO genotypes in severity of pulmonary disease in noninfected CF patients.
###end p 40
###begin title 41
ACKNOWLEDGMENTS
###end title 41
###begin p 42
The authors wish to thank Dr Pierre-Regis Burgel from Cochin Hospital for stimulating discussions, Dr Anh Thu Nguyen for data managing, and the excellent technical assistance of Nadya Mothu. This work was supported by the Association ABCF protein and Vaincre la Mucoviscidose (VWS and BDL) and by a grant to WF Reynold from the National Institutes of Health (RO1 AG17879). We thank the financial support of Baxter and AMGEN. This work has been presented as an oral communication at the 28th European Cystic Fibrosis Conference, Hersonissos, Crete, Greece, 22-25 June 2005.
###end p 42
###begin article-title 43
Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis
###end article-title 43
###begin article-title 44
Cystic fibrosis
###end article-title 44
###begin article-title 45
The role of inflammation in the pathophysiology of CF lung disease
###end article-title 45
###begin article-title 46
###xml 48 56 <span type="species:ncbi:9606">children</span>
Protease-antiprotease imbalance in the lungs of children with cystic fibrosis
###end article-title 46
###begin article-title 47
Neutrophils: molecules, functions and pathophysiological aspects
###end article-title 47
###begin article-title 48
Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum
###end article-title 48
###begin article-title 49
###xml 35 43 <span type="species:ncbi:9606">patients</span>
Management of pulmonary disease in patients with cystic fibrosis
###end article-title 49
###begin article-title 50
###xml 86 108 86 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pseudomonas aeruginosa</italic>
###xml 86 108 <span type="species:ncbi:287">Pseudomonas aeruginosa</span>
Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections
###end article-title 50
###begin article-title 51
NADPH oxidase: an update
###end article-title 51
###begin article-title 52
Activation of the neutrophil respiratory burst oxidase
###end article-title 52
###begin article-title 53
Myeloperoxidase
###end article-title 53
###begin article-title 54
Neutrophil-derived long-lived oxidants in cystic fibrosis sputum
###end article-title 54
###begin article-title 55
Myeloperoxidase and protein oxidation in cystic fibrosis
###end article-title 55
###begin article-title 56
Peroxidase activity within circulating neutrophils correlates with pulmonary phenotype in cystic fibrosis
###end article-title 56
###begin article-title 57
Disturbed mye-loperoxidase-dependent activity of neutrophils in cystic fibrosis homozygotes and heterozygotes, and its correction by amiloride
###end article-title 57
###begin article-title 58
An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element
###end article-title 58
###begin article-title 59
The consensus sequence of a major Alu subfamily contains a functional retinoic acid response element
###end article-title 59
###begin article-title 60
A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians
###end article-title 60
###begin article-title 61
###xml 118 126 <span type="species:ncbi:9606">patients</span>
A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients
###end article-title 61
###begin article-title 62
Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease
###end article-title 62
###begin article-title 63
Association between Alzheimer's disease and a functional polymorphism in the Myeloperoxidase gene
###end article-title 63
###begin article-title 64
Myeloperoxidase G-463A polymorphism and Alzheimer's disease in the ApoEurope study
###end article-title 64
###begin article-title 65
###xml 102 119 <span type="species:ncbi:11103">hepatitis C virus</span>
A genotypic association implicates myelo-peroxidase in the progression of hepatic fibrosis in chronic hepatitis C virus infection
###end article-title 65
###begin article-title 66
Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis
###end article-title 66
###begin article-title 67
Gender and smoking-related risk reduction of periodontal disease with variant myeloperoxidase alleles
###end article-title 67
###begin article-title 68
Myeloperoxidase genetic polymorphism and lung cancer risk
###end article-title 68
###begin article-title 69
A myeloperoxidase polymorphism associated with reduced risk of lung cancer
###end article-title 69
###begin article-title 70
Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism
###end article-title 70
###begin article-title 71
Inducible nitric oxide synthase expression is inhibited by myeloperoxidase
###end article-title 71
###begin article-title 72
SNPing away at innate immunity
###end article-title 72
###begin article-title 73
Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis
###end article-title 73
###begin article-title 74
###xml 8 9 8 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
An alpha1-antitrypsin enhancer polymorphism is a genetic modifier of pulmonary outcome in cystic fibrosis
###end article-title 74
###begin article-title 75
Phenotype of CF and the effects of possible modifier genes
###end article-title 75
###begin article-title 76
###xml 84 92 <span type="species:ncbi:9606">patients</span>
Nitric oxide synthase 1 as a potential modifier gene of decline in lung function in patients with cystic fibrosis
###end article-title 76
###begin article-title 77
###xml 36 44 <span type="species:ncbi:9606">patients</span>
Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period
###end article-title 77
###begin article-title 78
###xml 32 40 <span type="species:ncbi:9606">children</span>
Priming of blood neutrophils in children with cystic fibrosis: correlation between functional and phenotypic expression of opsonin receptors before and after platelet-activating factor priming
###end article-title 78
###begin article-title 79
Molecular characterization of cystic fibrosis: 16 Novel mutations identified by analysis of the whole cystic fibrosis conductance transmembrane regulator (CFTR) coding regions and splice site junctions
###end article-title 79
###begin article-title 80
Identification of 12 novel mutations in the CFTR gene
###end article-title 80
###begin article-title 81
###xml 48 56 <span type="species:ncbi:9606">patients</span>
A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations
###end article-title 81
###begin article-title 82
MPO and APOEepsilon4 polymorphisms interact to increase risk for AD in Finnish males
###end article-title 82
###begin article-title 83
Dysregulated NF-kappaB activation in cystic fibrosis: evidence for a primary inflammatory disorder
###end article-title 83
###begin article-title 84
###xml 40 45 <span type="species:ncbi:9606">human</span>
High susceptibility for cystic fibrosis human airway gland cells to produce IL-8 through the I kappa B kinase alpha pathway in response to extracellular NaCl content
###end article-title 84
###begin article-title 85
###xml 135 157 131 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pseudomonas aeruginosa</italic>
###xml 135 157 <span type="species:ncbi:287">Pseudomonas aeruginosa</span>
NF-kappaB activation and sustained IL-8 gene expression in primary cultures of cystic fibrosis airway epithelial cells stimulated with Pseudomonas aeruginosa
###end article-title 85
###begin article-title 86
###xml 27 49 27 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pseudomonas aeruginosa</italic>
###xml 27 49 <span type="species:ncbi:287">Pseudomonas aeruginosa</span>
###xml 87 92 <span type="species:ncbi:9606">human</span>
###xml 130 137 <span type="species:ncbi:9606">patient</span>
Effects of nitric oxide on Pseudomonas aeruginosa infection of epithelial cells from a human respiratory cell line derived from a patient with cystic fibrosis
###end article-title 86
###begin article-title 87
###xml 28 36 <span type="species:ncbi:9606">children</span>
NO pathway in CF and non-CF children
###end article-title 87
###begin article-title 88
Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure
###end article-title 88
###begin article-title 89
Oxidative stress causes mucin synthesis via transactivation of epidermal growth factor receptor: role of neutrophils
###end article-title 89
###begin article-title 90
Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease
###end article-title 90
###begin title 91
Figures and Tables
###end title 91
###begin p 92
###xml 170 171 170 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 193 194 193 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 270 271 270 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 298 299 298 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 404 405 402 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 419 420 417 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 54 62 <span type="species:ncbi:9606">patients</span>
###xml 64 67 <span type="species:ncbi:12672?0.125">FEV</span>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
###xml 255 263 <span type="species:ncbi:9606">patients</span>
Influence of MPO genotype on respiratory scores in CF patients. FEV % (on the left) and FVC % (on the right) were measured in (a) 21 noninfected CF patients either with (n = 14) for the GG or (n = 7) for the GA genotype and (b) 37 chronically infected CF patients with (n = 22) for the GG or with (n = 15) for the GA genotype. The data are the mean +/- SEM. Differences were statistically significant (* P = .03 and ** P < .001).
###end p 92
###begin p 93
###xml 52 60 <span type="species:ncbi:9606">children</span>
Frequencies of MPO genotype in the population of CF children.
###end p 93
###begin p 94
###xml 31 39 <span type="species:ncbi:9606">patients</span>
###xml 98 106 <span type="species:ncbi:9606">children</span>
###xml 193 201 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of CF patients stratified with their infectious status. A total of 77 CF children were studied and two groups were made up according to the infectious status of the CF patients. The data are the mean +/- SEM. The radio score indicates the number of lesions observed on the chest radiography. The ATB refers to the number of antibiotherapy treatment during the preceding year.
###end p 94
###begin p 95
###xml 483 484 481 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
###xml 279 287 <span type="species:ncbi:9606">children</span>
Influence of MPO genotype on clinical parameters of CF disease. The -463G/A MPO polymorphism was determined in 58 CF patients as described in the "methods." The influence of the polymorphism of MPO promoter was studied either in (a) noninfected or in (b) chronically infected CF children. The data are the mean +/- SEM. The radio score indicates the number of lesions seen on the chest radiography. The ATB means the number of antibiotherapy treatment during the preceding year. NS: P > .05.
###end p 95

